Evidence map›Paper›PMID 40618153›Full record

ArticleVirology journal2025

UMPlex™: a targeted next-generation sequencing primer design workflow.

Dachuan Lin, Xiaomin Zhang, Dan Wang, Tongyingzi Liu, Tong Li, Yingluan Zhang, Lihua Li, Yi Huang, Yongchao Guo, Renli Zhang and 2 more

Abstract read
In one paragraph

Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dachuan Lin *Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Hainan Medical University & Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University, Haikou, China.
Xiaomin Zhang *Shenzhen Center for Disease Control and Prevention, 8 Longyuan Rd, Shenzhen, 518055, China.
Dan Wang *Shenzhen Uni-Medica Technology Co., Ltd., Block 6th, Liuxian Culture Park, Shenzhen, China.
Tongyingzi LiuShenzhen Center for Disease Control and Prevention, 8 Longyuan Rd, Shenzhen, 518055, China.
Tong LiShenzhen Center for Disease Control and Prevention, 8 Longyuan Rd, Shenzhen, 518055, China.
Yingluan ZhangShenzhen Center for Disease Control and Prevention, 8 Longyuan Rd, Shenzhen, 518055, China.
Lihua LiHainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Hainan Medical University & Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University, Haikou, China.
Yi HuangHainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Hainan Medical University & Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University, Haikou, China.
Yongchao GuoShenzhen Uni-Medica Technology Co., Ltd., Block 6th, Liuxian Culture Park, Shenzhen, China. ycguo@uni-medica.com.
Renli ZhangShenzhen Center for Disease Control and Prevention, 8 Longyuan Rd, Shenzhen, 518055, China. renlizhangszcdc@aliyun.com.
Xinchun ChenGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Pathogen Biology, Shenzhen University Medical School, Shenzhen, 518060, China. chenxinchun@szu.edu.cn.
Tiejian FengShenzhen Center for Disease Control and Prevention, 8 Longyuan Rd, Shenzhen, 518055, China. fengtiej@126.com.ORCID 0000-0001-8217-6269

Funding

Guang Dong Basic and Applied Basic Research Foundation 2024A1515030195
6 · The paper itself

Abstract

We have developed a tailored next-generation sequencing (tNGS) panel, employing our innovative UMPlex™ primer design workflow, to enhance pathogen identification in clinical diagnostics. Through iterative experimentation and rigorous validation, we refined the primer design by excluding those with insufficient specificity or efficiency. To mitigate amplification challenges arising from pathogenic mutations, we implemented a strategy of using a minimum of two primer pairs per pathogen, ensuring redundancy and robust detection. Validation using clinical samples showcased high specificity and efficacy, with 11 cultured pathogens isolated exclusively. In a study involving 107 positive respiratory samples, tNGS outperformed the TaqMan Array, detecting a higher number of pathogens in patients with influenza-like symptoms of unknown etiology. Additionally, tNGS yielded higher read counts for potentially pathogenic microorganisms and produced results consistent with metagenomic NGS, despite generating a reduced data volume. This approach not only improves detection rates but also offers a flexible tool for both clinical diagnostics and surveillance, particularly in the context of influenza-like illnesses.

Indexed as

DNA PrimersHigh-Throughput Nucleotide SequencingMolecular Diagnostic TechniquesHumansInfluenza, HumanSensitivity and SpecificityWorkflowDNA PrimersClinical surveillanceInfluenza-like patientsPersonalized primer designTargeted next-generation sequencing

Identifiers

PMID40618153
PMCPMC12228999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.